The Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with Revlimid (lenalidomide) and Rituxan (rituximab) for the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL). This includes patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma (HGBL), following two or more lines of systemic therapy and those who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR-T-cell therapy, according to the agency.
Glossary
Autologous hematopoietic stem cell transplantation (auto-HSCT): When a patient’s healthy blood-forming cells are collected before treatment, stored, then given back after treatment.
CAR-T cell therapy: When a patient’s T cells are collected, changed in a laboratory to attack cancer cells, grown in the laboratory and returned to the patient.
Overall survival (OS): The time a patient lives, regardless of disease status.
Progression-free survival: The time a patient lives without their disease spreading or worsening.
Objective response rate: Patients who responded partially or completely to treatment.
Peripheral neuropathy: A condition causing weakness, numbness or pain in the extremities.
This FDA approval was based on data from the phase 3 ECHELON-3 clinical trial which evaluated 230 patients with relapsed or refractory LBCL who were ineligible for auto-HSCT or CAR-T cell therapy. In the trial, Adcetris plus Revlimid and Rituxan (BV+R2) was compared with placebo plus Revlimid and Rituxan (Pbo+R2), resulting in a statistically significant improvement in overall survival (OS) with the investigative combination.
The median OS was 13.8 months in the BV+R2 arm and 8.5 months in the Pbo+R2 arm. Additionally, the median progression-free survival times were 4.2 months and 2.6 months, respectively, and the objective response rates were 64.3% and 41.5%.
The most common side effects experienced by at least 20% of patients, excluding laboratory abnormalities, in the BV+R2 arm were fatigue, diarrhea, peripheral neuropathy, rash, pneumonia and COVID-19 infection, while grade 3 (severe) to 4 (life-threatening) laboratory abnormalities experienced by more than 10% of patients included decreased neutrophils, decreased lymphocytes, decreased platelets and decreased hemoglobin. The agency reported that peripheral neuropathy developed or worsened in 27% of patients, was predominantly sensory and led to Adcetris dose reduction in 6% of patients and discontinuation in 4.5%.
The recommended dose of Adcetris is 1.2 milligrams per kilogram to a maximum of 120 milligrams in combination with Revlimid and Rituxan administered every three weeks until disease progression or unacceptable toxicity.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
